ArticleCancer discovery2025
Presence of Tertiary Lymphoid Structures and Exhausted Tissue-Resident T Cells Determines Clinical Response to PD-1 Blockade in Renal Cell Carcinoma.
Abstract read
In one paragraph
Article in Cancer discovery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers.
0numbers the graph read from it
0cells of the map it votes in
44citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed.
- Dissecting the Tumor Microenvironment to Identify Biomarkers of Outcome to Anti-PD-1 Therapy in Clear-Cell Renal Cell Carcinoma: Analyses of the HCRN GU16-260 Trial.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Trial
- Stereotactic body radiation therapy enriches mediators of humoral immune activity in metastatic renal cell carcinoma.Journal for immunotherapy of cancer · 2026Article
- Heterogeneity in cancer: molecular mechanisms and therapeutic strategies.Signal transduction and targeted therapy · 2026Review
- Renal cell carcinoma: molecular understanding and therapeutic development.Cell death and differentiation · 2026Review
- Gastric cancer tertiary lymphoid structures in the muscularis propria are associated with therapy resistance and promote immunosuppression.Nature communications · 2026Article
- Fusion-driven oncogenic programs shape the immune landscape in translocation renal cell carcinoma.Nature communications · 2026Article
- Article
- Multi-omic characterization of 14q deletion in renal clear cell carcinoma identifiesJournal for immunotherapy of cancer · 2026Article
- Beyond TLS Presence: A Functional Framework Integrating Maturity, Location, and Immune Context.Cancers · 2026Review
- Radiotherapy and tertiary lymphoid structures: balancing immune activation and immune damage in cancer immunotherapy.Molecular cancer · 2026Review
- Hypoxia shapes both therapeutic response and resistance in metastatic clear cell renal cell carcinoma.Cancer cell · 2026Article
- An immunogenomic classification of solid tumours reveals subtype-specific therapeutic vulnerabilities for immunotherapy.EBioMedicine · 2026Article
- Cancer-associated fibroblasts and tertiary lymphoid structure orchestrate the spatial architecture of tumor immunity.Journal of hematology & oncology · 2026Review
- The seventh kidney cancer research summit: progress in accelerating cures.The oncologist · 2026Article
- Review
- Immunotherapy Landscape of Advanced Clear Cell Renal Cell Carcinoma: Targeting the Cancer-Immunity Cycle and Future Perspectives.Biomedicines · 2026Review
- Natural Products in Clear Cell Renal Cell Carcinoma: Rewiring the VHL-HIF Axis, Metabolic Plasticity, and Tumor-Immune Interactions.International journal of molecular sciences · 2026Review
- Single-Cell Atlas of Renal Cell Carcinoma Brain Metastasis Uncovers Mechanisms of Immune Dysfunction and Resistance.bioRxiv : the preprint server for biology · 2026Article
- Association of Circulating T Cell and Tumor Microenvironment Profiles with Immune Checkpoint Blockade Outcomes in Sarcoma.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
27 authors.
Miya B Hugaboom *Yale Cancer Center, Yale University School of Medicine, New Haven, Connecticut.ORCID 0000-0001-8099-3564
Lena V Wirth *Yale Cancer Center, Yale University School of Medicine, New Haven, Connecticut.ORCID 0000-0001-7776-2853
Kelly Street *Division of Biostatistics, Keck School of Medicine of USC, Los Angeles, California.ORCID 0000-0001-6379-5013
Neil Ruthen *Weill Cornell Graduate School of Medical Sciences, New York, New York.ORCID 0000-0002-4409-9503
Opeyemi A JegedeDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.ORCID 0000-0003-1763-8214
Nicholas R SchindlerYale Cancer Center, Yale University School of Medicine, New Haven, Connecticut.ORCID 0000-0003-2277-7729
Valisha ShahDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.ORCID 0009-0000-7396-8184
Jacob P ZaemesGeorgetown Lombardi Comprehensive Cancer Center, Washington, District of Columbia.ORCID 0009-0007-4390-5490
Nourhan El AhmarDepartment of Pathology, Brigham and Women's Hospital, Boston, Massachusetts.ORCID 0000-0002-9348-204X
Sayed MatarDepartment of Pathology, Brigham and Women's Hospital, Boston, Massachusetts.ORCID 0000-0002-9687-2318
Varunika SavlaDepartment of Pathology, Brigham and Women's Hospital, Boston, Massachusetts.ORCID 0009-0002-0281-5628
Toni K ChoueiriDepartment of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.ORCID 0000-0002-9201-3217
Thomas DenizeDepartment of Pathology, Brigham and Women's Hospital, Boston, Massachusetts.ORCID 0000-0002-8618-7691
Destiny J WestDepartment of Pathology, Brigham and Women's Hospital, Boston, Massachusetts.ORCID 0009-0004-5960-5271
David F McDermottDivision of Medical Oncology, Beth Israel Deaconess Medical Center, Boston, Massachusetts.ORCID 0000-0002-2675-5095
Elizabeth R PlimackFox Chase Cancer Center, Temple Health, Philadelphia, Pennsylvania.ORCID 0000-0002-7618-0744
Jeffrey A SosmanRobert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago, Illinois.ORCID 0000-0002-0650-9698
Naomi B HaasAbramson Cancer Center, University of Pennsylvania, Philadelphia, Pennsylvania.ORCID 0000-0001-8907-7968
Mark N SteinHerbert Irving Comprehensive Cancer Center, Columbia University, New York, New York.ORCID 0000-0002-0853-3640
Robert AlterHackensack University Medical Center, Hackensack, New Jersey.ORCID 0009-0008-5990-3905
Mehmet A BilenWinship Cancer Institute, Emory University, Atlanta, Georgia.ORCID 0000-0003-4003-1103
Michael E HurwitzYale Cancer Center, Yale University School of Medicine, New Haven, Connecticut.ORCID 0000-0002-1326-7308
Hans HammersDivision of Hematology and Oncology, Department of Internal Medicine, UT Southwestern Medical Center, Dallas, Texas.ORCID 0000-0002-6224-4559
Sabina SignorettiDepartment of Pathology, Brigham and Women's Hospital, Boston, Massachusetts.ORCID 0000-0002-5000-9105
Michael B Atkins *Georgetown Lombardi Comprehensive Cancer Center, Washington, District of Columbia.ORCID 0000-0003-3901-9924
Catherine J Wu *Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, Massachusetts.ORCID 0000-0002-3348-5054
David A Braun *Yale Cancer Center, Yale University School of Medicine, New Haven, Connecticut.ORCID 0000-0003-4543-5553
Funding
Yale Pathology Tissue Services Shared ResourceP30CA016359 · NCI · YALE UNIVERSITY · PI DAVID L RIMM · 1985 to 2026
$85.0MTissue Culture Shared ResourceP30CA051008 · NCI · GEORGETOWN UNIVERSITY · PI STEPHEN W BYERS · 1990 to 2026
$71.5MTreating the P13-Kinase/AKTP50CA101942 · NCI · BETH ISRAEL DEACONESS MEDICAL CENTER · PI Wanling Xie · 2003 to 2026
$53.4MPhysician Scientist Training in Cancer ResearchT32CA009172 · NCI · DANA-FARBER CANCER INSTITUTE · PI Jennifer R Brown, James A. DeCaprio · 1985 to 2026
$17.1MINTERDISCIPLINARY IMMUNOLOGY TRAINING PROGRAMT32AI007019 · NIAID · YALE UNIVERSITY · PI Carrie L. Lucas, David G. Schatz · 1985 to 2026
$14.4MTumor and immune determinants of effective anti-tumor immunity in renal cell carcinomaR37CA279822 · NCI · YALE UNIVERSITY · PI David Braun · 2023 to 2026
$2.6MFlow cytometer for high-parameter analysesS10OD026996 · OD · YALE UNIVERSITY · PI HABERMAN, ANN M · 2019 to 2019
$596kBristol Myers Squibb Foundation (BMSF) CA209-669National Cancer Institute (NCI) 1R37CA279822-01National Cancer Institute (NCI) NCI P30CA051008National Cancer Institute (NCI) NCI P50CA101942NCI NIH HHS P30 CA016359NCI NIH HHS P30 CA051008NCI NIH HHS P50 CA101942NCI NIH HHS R37 CA279822NCI NIH HHS T32 CA009172NIAID NIH HHS T32 AI007019NIH HHS S10 OD026996U.S. Department of Defense (DOD) KC170216/W81XWH-18-1-0367U.S. Department of Defense (DOD) KC190128/W81XWH-20-1-0882 and KC220016/HT9425-23-1-0735U.S. Department of Defense (DOD) KC200280/W81XWH-21-1-0808
Abstract
significanceWe describe a paradigm wherein combined high TLS and low tissue-resident exhausted CD8+ T cells are required for optimal response to PD-1 blockade in RCC. This analysis identifies key determinants of response to PD-1 blockade in advanced RCC and suggests avenues for future immune modulation through rational combination therapy strategies.
Indexed as
Carcinoma, Renal CellCD8-Positive T-LymphocytesImmune Checkpoint InhibitorsKidney NeoplasmsProgrammed Cell Death 1 ReceptorTertiary Lymphoid StructuresHumansMaleImmune Checkpoint InhibitorsPDCD1 protein, humanProgrammed Cell Death 1 Receptor
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.